Revenue and Financial Performance - For the year ended January 31, 2024, the company generated revenue of 2,085,314,aslightincreasefrom2,079,609 in the previous year, with costs of revenue at 1,223,209comparedto1,329,200[178]. - The company reported a net loss of 5,485,314,or(0.69) per share, for the year ended January 31, 2024, compared to a loss of 4,483,474,or(0.53) per share, for the previous year[183]. - For the year ended January 31, 2024, the Company incurred a net loss from operations of 4,871,926andusedcashflowfromoperationsof3,527,509[191]. - The company’s total revenue from contract manufacturing services was 1,920,280fortheyearendedJanuary31,2024[178].Expenses−Thecompanyincurredresearchanddevelopmentexpensesof1,960,425 for its Aversa Fentanyl product, up from 982,227inthepreviousyear[181].−Selling,generalandadministrativeexpensesdecreasedto3,773,606 for the year ended January 31, 2024, from 3,916,041intheprioryear[179].−Thecompanyrecordedbaddebtexpensesof118,364 for doubtful accounts related to accounts receivable for the year ended January 31, 2024[201]. - The company’s interest expense increased to 75,815fortheyearendedJanuary31,2024,comparedto6,289 in the previous year[183]. - The company recorded an impairment expense of 327,326inthepreviousyearduetoawrite−downofgoodwillrelatedtoitsPoconoacquisition[180].CashandFinancing−AsofJanuary31,2024,thecompanyhadcashandcashequivalentsof492,942, down from 1,985,440ayearearlier[184].−Thecompanycompletedan8,400,000 equity financing with European investors on April 19, 2024, consisting of 2,100,000 units at a price of 4.00perunit[177].−TheCompanyenteredintoathree−year5,000,000 Credit Line Note facility to fund research and development of its Aversa product[191]. - The Company recorded proceeds of 8,400,000fromaprivateplacementofitscommonstockonApril19,2024[191].InventoryandAssets−AsofJanuary31,2024,totalinventorywas168,605, a decrease from 229,335asofJanuary31,2023[204].−Goodwillamountedto5,021,713 as of January 31, 2024, unchanged from the previous year[207]. Future Outlook - The Company believes it will generate sufficient funds from operations to continue for one year from the date of the financial statements[192]. - The Company has generated operating losses since inception and has relied on sales of securities and debt issuance to support cash flow[191]. - Research and development costs are expensed as incurred, reflecting the Company's commitment to innovation[214]. Capital Requirements - The company has a capital requirement of approximately $13 million for the research and development of its abuse deterrent fentanyl transdermal system[169].